Public Calendar: March 21-27 2021
This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.
Official Name: Janet Woodcock, M.D., Acting Commissioner
Event Date: 03/23/2021
Location: Virtual
Subject: Update from Critical Path Institute
FDA Participant/Group: N/A
Non FDA Participant/Group: Joseph Scheeren, Timothy Franson (Critical Path Institute);
Event Date: 03/23/2021
Location: Virtal
Subject: Making It Plain: A COVID-19 Town Hall for Minority Health Professionals
FDA Participant/Group: DAYLE CRISTINZIO;
Non FDA Participant/Group: Government, academia, industry and media
Event Date: 03/24/2021
Location: Virtual
Subject: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Weekly Trial Oversight Committee Meeting
FDA Participant/Group: PETER STEIN; KEVIN BUGIN;
Non FDA Participant/Group: Government, industry, academia and other invited guests
Event Date: 03/25/2021
Location: Virtual
Subject: The National Academies of Sciences Engineering Medicine Forum on Drug Discovery, Development and Translation
FDA Participant/Group: N/A
Non FDA Participant/Group: Academia, industry, and other invited guests
Event Date: 03/26/2021
Location: Virtual
Subject: Community Based Research Collaborations
FDA Participant/Group: Several FDA staff
Non FDA Participant/Group: Keith Fernandez (Privia Health); Jennifer Byrne, Linda McCarty, Thomas Pike (Javara Incorporated);
Official Name: Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner
Event Date: 03/22/2021
Location: Virtual
Subject: Harvard Medical School: Health Technology Innovation
FDA Participant/Group: N/A
Non FDA Participant/Group: Academia, industry, and other stakeholders
Event Date: 03/25/2021
Location: Virtual
Subject: COVID-19 Evidence Accelerator Lab Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Academia, industry, and other stakeholders
Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs
No Significant Event
Official Name: Jim Sigg, Deputy Commissioner for Operations
No Significant Event
Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response
Event Date: 03/26/2021
Location: Virtual
Subject: Food Safety Issues of Mutual Interest
FDA Participant/Group: N/A
Non FDA Participant/Group: Several staff and members from the Food Industry Association
Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy
No Significant Event
Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs
No Significant Event
Official Name: Heidi Rebello, Acting Associate Commissioner for External Affairs
No Significant Event
Official Name: RADM Denise Hinton, Chief Scientist
No Significant Event
Official Name: Patrizia Cavazzoni, M.D., Acting Director, Center for Drug Evaluation and Research
No Significant Event
Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
No Significant Event
Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health
No Significant Event
Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition
Event Date: 03/25/2021
Location: Virtual
Subject: Tufts University Online Retailing and Food Labeling Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, academia, and other stakeholders
Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products
Event Date: 03/25/2021
Location: Virtual
Subject: Listening Session with Reynolds American, Inc.
FDA Participant/Group: MICHELE MITAL; ESHAEL JOHNSON;
Non FDA Participant/Group: Several staff from Reynolds American, Inc.
Official Name: Steven Solomon, Director, Center for Veterinary Medicine
No Significant Event
Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research
No Significant Event
Official Name: Mark Raza, J.D., Acting Chief Counsel
Event Date: 03/24/2021
Location: Virtual
Subject: Synthetic Nicotine Preemption Meeting
FDA Participant/Group: ELIZABETH DICKINSON; SARAH STEWART; KAREN SCHIFTER; PERHAM GORJI; DAVID MEDNICK;
Non FDA Participant/Group: Andrew Goldfarb, William B. Schultz (Zuckerman Spaeder); Denny Henigan, Swati Rawani (Campaign for Tobacco Free Kids);